Sponsors
Founding Platinum
Wilson Sonsini Goodrich & Rosati
Wilson Sonsini Goodrich & Rosati is the premier provider of legal services to technology, life sciences, and growth enterprises worldwide and has one of the largest life sciences practices in the United States. The firm has a 60-plus-year history of representing trailblazers in the life sciences industry, from the earliest innovators to those shaping the future of healthcare today. Our multidisciplinary team of attorneys, patent agents, and scientific advisors works closely with entrepreneurs, scientists, and investors who trust the firm’s strategic advice to establish and realize their companies’ business objectives, which includes protecting and leveraging their most valuable IP assets. We represent life sciences companies through the entire business life cycle, from formation through IPO and strategic partnerships, and often act as outside general counsel with support from our cross-functional, global life sciences team. Our clients include thousands of innovation-focused life sciences companies, research institutions, start-up accelerators and incubators, and the venture capital funds and banks that finance the industry.
In Collaboration with
Shanghai Center of Biomedicine Development
Established in 1994, Shanghai Center of Biomedicine Development (SCBD) is an second-class scientific research institution directly administrated by Science & Technology Commission of Shanghai Municipality (STCSM). The main functions include undertaking researches related to technological innovation and industrial development in the fields of life sciences and biomedicine in Shanghai, common technology R&D, project management and services, construction of sci-tech innovation bases, transformation of scientific and technological achievements, investment promotion and enterprise services, talent training, as well as management services for human genetic resources and laboratory animals.
Silver
Hankang Capital
Founded in 2015, Hankang Capital is a specialized venture capital firm dedicated to the biotech industry. Headquartered in Shanghai with a strategic presence in Beijing and Hong Kong, we are positioned to bridge China’s R&D excellence with global innovation. Guided by our mission to “Empower Biomedical Innovation and Safeguard Human Health”, we partner with visionary entrepreneurs to provide end-to-end support across the entire drug development lifecycle, and our goal is to advance breakthrough therapeutics that address critical unmet medical needs across major therapeutic areas and diverse modalities on a global scale. To date, Hankang Capital has invested in over 50 high-potential companies, fostering industry leaders such as Akesobio, InnoCare, Keymed Biosciences, Abbisko, DualityBio, and Leads Biolabs. Our portfolio has built a consistent track record of successful IPOs on the HKEX and A-share markets, alongside extensive out-licensing and co-development partnerships with global MNCs. With multiple drug candidates having received regulatory approvals from the NMPA and FDA, Hankang remains committed to delivering lasting clinical value and investment impact.
Silver
RA Capital Management
RA Capital Management 成立于 2004 年，是一家专注于医疗健康、生命科学及地球健康（planetary health）领域的多阶段投资管理机构。公司秉持 “Evidence-Based（循证）” 的投资理念，投资于开发药物、诊断产品、医疗器械以及医疗健康工具与服务的上市与非上市企业。RA Capital 通过从早期私募种子轮到上市公司后续融资的多阶段资本支持，创建并投资创新型公司，使管理团队能够在公司创立、产品开发、商业化及长期发展的全过程中持续创造价值。公司的投资体系由以科学为核心的内部研究团队 TechAtlas 驱动，确保科学与临床证据在研究、投资决策及公司构建过程中发挥核心作用。此外，RA Capital 还运营医疗健康企业孵化器 Raven，为创业者和创新团队提供协作化、系统化的企业构建平台与资源支持，推动前沿生物医学创新从概念走向产业化。目前，RA Capital 拥有 250 余名员工，管理资产规模超过 140 亿美元。
Strategic Partner
Ascentage Pharma
Ascentage Pharma is a global, commercial stage, integrated biopharmaceutical company engaged in discovering, developing and commercializing therapies to address global unmet medical needs in cancer. On October 28, 2019, the Company was listed on the Main Board of HKEX (stock code: 6855.HK). On January 24, 2025, the Company was listed on NASDAQ (stock code: AAPG), becoming the first biopharmaceutical company to complete dual primary listing sequentially on the Hong Kong Stock Exchange and then on NASDAQ.
Ascentage Pharma has a world-class innovative, and highly derisked late stage pipeline, including 13 registrational Phase III clinical studies (completed or ongoing), of which 4 have been approved by the FDA and EMA. The Company’s two products, Olverembatinib and Lisaftoclax, have been approved for marketing in China. All approved indications of Olverembatinib have been included in the China NRDL.
Strategic Partner
JP Morgan
J.P. Morgan partners with healthcare leaders to deliver strategic advice and capital at scale. Our dedicated Healthcare Investment Banking franchise advises across the full spectrum of transactions—M&A, divestitures, joint ventures, and shareholder advisory—and raises capital through equity, equity‑linked, and debt markets, as well as private capital and structured solutions. Spanning biopharma, medtech, tools and diagnostics, and services like providers, payers, and healthtech, we combine deep sector expertise with the reach of a global platform, integrating banking and markets capabilities to help clients fund innovation, execute with certainty, and build resilient, growing enterprises.
Strategic Partner
METiS TechBio
Unlocking a healthier world through AI-driven nanotechnology. METiS Technologies is a pioneering TechBio company at the intersection of artificial intelligence and nanomaterial science, focused on transforming the delivery and application of active agents across life forms.
Founded by a team of MIT-trained scientists with deep expertise in AI, quantum mechanics, nanomaterials, and advanced drug delivery, the company has developed NanoForge, the world’s first AI-drive nano-delivery platform and three proprietary platform technologies, AiLNP – AI platform for nucleic acid delivery system design; AiRNA – AI platform for mRNA sequence optimization; and AiTEM – AI platform for small molecule formulation design.
METiS’ platforms simulate, predict, and interpret nanoscale interactions to enable rational design, optimization, and validation of next-generation nanomaterials and their payloads. By advancing AI-enabled nanotechnology, METiS strives to unlock new therapeutic possibilities across a wide range of diseases, including cancer, metabolic and autoimmune disorders, and neurodegenerative conditions, and improve the health of lives.
Strategic Partner
Tigermed
Tigermed (Stock code: 300347.SZ/3347.HK) is a leading provider of innovative clinical research solutions across the full life cycle of biopharmaceutical and medical device products globally. With a broad portfolio of services and a promise of quality, from clinical development to commercialization, we are committed to moving our customers and patients through their development journey efficiently and cost-effectively. Tigermed currently represents a worldwide network of more than 100 subsidiaries and 180 service locations, with over 10,000 employees across 50 countries in Asia Pacific, Europe, North & South America and Africa. We are devoted to building an integrated platform that enables boundless possibilities for healthcare industry, embracing challenges to fulfil our commitment to serve unmet patients’ needs, and eventually saving lives.
Supported By
13TH CHINA HEALTHCARE SUMMIT
China’s biotech sector is transforming how new medicines are discovered, tested and brought to market.
From cross-border deals to NewCos, faster clinical data is fueling the China innovation story, turning local biopharmas into global players. Pharmas and VCs are sourcing assets at an unprecedented clip and Western and Asia innovators are leveraging China partners to de-risk pipelines.
Don't miss out! Join us to explore cross-border opportunities, expand your network, and get a firsthand look at China's life sciences ecosystem.
Supported By
BayHelix Group
BayHelix Group is a non-profit, invitation-only organization of business leaders of Chinese heritage that fosters the growth of the life sciences and healthcare industry around the Pacific Rim and beyond. Founded in 2001, BayHelix has grown to over 300 members throughout the U.S., Canada, and Greater China. The membership base covers virtually all of the world’s top pharmaceutical and biopharmaceutical companies, as well as leading services and investment firms. Over one third of the members are senior executives, over 80% have PhDs in the life sciences, and nearly half have MBAs from the leading business schools in U.S.
Supported By
Lychee Group
Our mission is simple: create the best, most innovative events to provide you with the latest business information and the greatest opportunity to network with your peers and new potential business partners.
Since 2008, Lychee Group has helped launch some of the longest running and most reputable life sciences conferences in China including: ChinaTrials: Clinical Development Leaders' Summit, China Healthcare Investment Conference (CHIC), China Medical Affairs Summit, DeviceChina, BioCentury's China Healthcare Summit and Healthcare Capital & Connections Summit (HCCS).
Supported By
PharmaDJ
Cofounded by experienced journalists and editors in 2014, PharmaDJ is the leading business intelligence and media portal for Pharmaceutical and Biotech industry in China. Since then, it has built a wide platform to serve the industry need. Now, it provides different services including business intelligence, business strategy consulting and conference/training program to its readers and clients. With the editorial team located in Shanghai, Guangzhou, Beijing, Suzhou, New Jersey and Hawii, our focus covers the entire drug life cycle, from early drug research, translational science, clinical development, commercial, market access and PR communication strategies. Every day, our voice reaches thousands of industry executives, investors and regulators through our multi-media platforms that consist of website, WeChat, Xueqiu, Toutiao, LinkedIn and more. With the mission to become the lighthouse for the Chinese pharmaceutical industry, we will continue our journey to facilitate the development of pharmaceutical industry.